PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34557659-0	2021	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.	srx3262	33-40	bromodomain containing 4	Homo sapiens	13-17	
34557659-2	2021	Here, we developed the first-in-class BTK/PI3K/BRD4 axis inhibitor SRX3262, which simultaneously blocks three interrelated MCL driver pathways - BTK, PI3K-AKT-mTOR and MYC.	srx3262	67-74	bromodomain containing 4	Homo sapiens	47-51	
34557659-3	2021	SRX3262 concomitantly binds to BTK, PI3K, and BRD4, exhibits potent in vitro and in vivo activity against MCL, and overcomes the Ibrutinib resistance resulting from the BTK-C481S mutation.	srx3262	0-7	bromodomain containing 4	Homo sapiens	46-50	
34557659-4	2021	Our results reveal that SRX3262 inhibits IgM-induced BTK and AKT phosphorylation and abrogates binding of BRD4 to MYC loci.	srx3262	24-31	bromodomain containing 4	Homo sapiens	106-110